Lilly to bag Loxo Oncology for $8 billion

8 Jan 2019

Acquisition will broaden the scope of Lilly's oncology portfolio into precision medicines.

Eli Lilly and Loxo Oncology have announced a definitive agreement for Lilly to acquire Loxo Oncology for $235.00 per share in cash, or approximately $8.0 billion. Loxo Oncology is a biopharmaceutical company focused on the development and commercialization of highly selective medicines for patients with genomically defined cancers.

Lilly to bag Loxo Oncology for $8 billion

The acquisition would be the largest and latest in a series of transactions Lilly has conducted to broaden its cancer treatment efforts with externally sourced opportunities for first-in-class and best-in-class therapies. Loxo Oncology is developing a pipeline of targeted medicines focused on cancers that are uniquely dependent on single gene abnormalities that can be detected by genomic testing. For patients with cancers that harbor these genomic alterations, a targeted medicine could have the potential to treat the cancer with dramatic effect.

Loxo Oncology has a promising portfolio of approved and investigational medicines, including

  • LOXO-292, a first-in-class oral RET inhibitor that has been granted Breakthrough Therapy designation by the FDA for three indications, with an initial potential launch in 2020. LOXO-292 targets cancers with alterations to the rearranged during transfection (RET) kinase. RET fusions and mutations occur across multiple tumor types, including certain lung and thyroid cancers as well as a subset of other cancers.
  • LOXO-305, an oral BTK inhibitor currently in Phase I/II. LOXO-305 targets cancers with alterations to the Bruton's tyrosine kinase (BTK), and is designed to address acquired resistance to currently available BTK inhibitors. BTK is a validated molecular target found across numerous B-cell leukemias and lymphomas.
  • Vitrakvi, a first-in-class oral TRK inhibitor developed and commercialized in collaboration with Bayer that was recently approved by the FDA. Vitrakvi is the first treatment that targets a specific genetic abnormality to receive a tumour-agnostic indication at the time of initial FDA approval.
  • LOXO-195, a follow-on TRK inhibitor also being studied by Loxo Oncology and Bayer for acquired resistance to TRK inhibition, with a potential launch in 2022.
  • "Using tailored medicines to target key tumour dependencies offers an increasingly robust approach to cancer treatment," said Daniel Skovronsky, Lilly's chief scientific officer and president of Lilly Research Laboratories. "Loxo Oncology's portfolio of RET, BTK and TRK inhibitors targeted specifically to patients with mutations or fusions in these genes, in combination with advanced diagnostics that allow us to know exactly which patients may benefit, creates new opportunities to improve the lives of people with advanced cancer."

    "We are gratified that Lilly has recognized our contributions to the field of precision medicine and are excited to see our pipeline benefit from the resources and global reach of the Lilly organization," said Josh Bilenker, CEO of Loxo Oncology. "Tumour genomic profiling is becoming standard-of-care, and it will be critical to continue innovating against new targets, while anticipating mechanisms of resistance to available therapies, so that patients with advanced cancer have the chance to live longer and better lives."

    "Lilly Oncology is committed to developing innovative, breakthrough medicines that will make a meaningful difference for people with cancer and help them live longer, healthier lives," said Anne White, president of Lilly Oncology. "The acquisition of Loxo Oncology represents an exciting and immediate opportunity to expand the breadth of our portfolio into precision medicines and target cancers that are caused by specific gene abnormalities. The ability to target tumor dependencies in these populations is a key part of our Lilly Oncology strategy. We look forward to continuing to advance the pioneering scientific innovation begun by Loxo Oncology."

    "We are excited to have reached this agreement with a team that shares our commitment to ensuring that emerging translational science reaches patients in need," said Jacob Van Naarden, chief operating officer of Loxo Oncology. "We are confident that the work we have started, which includes an FDA approved drug, and a pipeline spanning from Phase II to discovery, will continue to thrive in Lilly's hands."

    Read More

    Related tags

    Market News

    Related news

    Allergan to establish R&D presence in Cambridge, Massachusetts

    Allergan to establish R&D presence in Cambridge, Massachusetts

    10 Jan 2019

    The new, strategic presence will allow the company to more easily interact and engage with venture firms and start ups in the area.

    Read more 
    Expedeon signs supply and license agreement for is Lightning-Link technology

    Expedeon signs supply and license agreement for is Lightning-Link technology

    9 Jan 2019

    The technology will enable Cell Guidance Systems to manufacture TRIFic detection assays on-demand with highly reproducible and scalable results.

    Read more 
    Catalent to double its commercial biomanufacturing capacity

    Catalent to double its commercial biomanufacturing capacity

    7 Jan 2019

    The $200-million expansion will support customers’ development programs and commercial launches.

    Read more 
    BMS and Celgene merge to create premier innovative biopharma company

    BMS and Celgene merge to create premier innovative biopharma company

    3 Jan 2019

    Significantly expands Phase III assets with six expected near-term product launches, representing greater than $15 billion in revenue potential.

    Read more 
    Cambrex completes acquisition of Avista Pharma Solutions

    Cambrex completes acquisition of Avista Pharma Solutions

    2 Jan 2019

    Acquisition adds a full complement of early-stage development capabilities to Cambrex’s larger scale capabilities for APIs and finished dosage forms.

    Read more 
    Novartis offers to acquire CellforCure

    Novartis offers to acquire CellforCure

    1 Jan 2019

    Proposed acquisition will expand manufacturing capacity for innovative cell and gene therapies.

    Read more 
    BMS receives offer from Taisho to purchase UPSA

    BMS receives offer from Taisho to purchase UPSA

    30 Dec 2018

    The potential transaction would position BMS to further refine its portfolio to focus on transformational medicines for patients facing serious diseases.

    Read more 
    Recipharm to potentially end operations in Ashton-under-Lyne facility

    Recipharm to potentially end operations in Ashton-under-Lyne facility

    24 Dec 2018

    The operation has not been profitable for several years; no likely prospect of it being able to deliver an acceptable return in the medium term.

    Read more 
    An increased risk of a hard or ‘no deal Brexit?

    An increased risk of a hard or ‘no deal Brexit?

    24 Dec 2018

    A ‘no deal’ Brexit will change and burden how all industries that move materials and goods across borders, including the pharmaceutical and medical device sectors, do business.

    Read more 
    Alcon acquires Tear Film Innovations

    Alcon acquires Tear Film Innovations

    20 Dec 2018

    Tear Film's iLux Device offers innovative, customizable treatment for Meibomian Gland Dysfunction, a leading cause of dry eye.

    Read more